X

The Envigo brand story

At Envigo, we are proud of our customer-centric culture which makes us responsive to every customer, no matter their size, continually optimizing their research programs to ensure consistently clear results. Learn more

Corporate social responsibility

Corporate social responsibility (CSR) has always been part of the way we’ve done business—it's what we do and how we do it. Learn more

Research models

Use our advanced search tool below to find the exact model you need.

 

Quick Links

Health monitoring reports
Genetic monitoring reports
Cell line references

Envigo launches R2G2 double knockout mouse model

Unique mixed background mouse enables researchers to examine effects of a wider range of radiation dosages. Read More

Envigo expands R&D capabilities in non-animal technologies to meet regulatory and market requirements for in vitro assays

From 2018 onwards, Envigo expects to create between five to ten new in vitro and in silico tests on average per year. This demand for such tests is fuelled by changing regulatory environments as well as technological and scientific advancements that are making robust in vitro tests possible. Read More

Envigo's fully validated highly sensitive method enables completion of thyroid hormone tests in accordance with OECD guidelines

Liquid chromatography-mass spectrometry technique can detect T3 and T4 levels in 4 and 13 day old F1 rats. Read More

See All Latest News
Brochure
Envigo oncology brochure (USA | EU)

At Envigo, we understand that our customers conduct research and develop products that have the potential to offer significant improvements to global health and the environment. We also realize achieving that potential has grown more challenging. That is why we remain focused on your goals, needs and expectations, ensuring you have a trusted partner to advance your life-changing research and products.

Article
Developments in LifeSciences Vol. 15, No. 1

In this issue:
• 20 critical questions for ensuring inhaled crop protection and chemical registration
• The CRO landscape — An evolving safety testing market
• Substance identity: The critical component of both lead and co-registrant dossiers
• The extended one-generation reproductive toxicity study (EOGRTS), OECD test guideline 443

Webinar on-demand
Key considerations in the safety evaluation of drugs targeting immune checkpoints

Presented by Lee Coney (Chief Scientific Officer - Biologics) and Mandy Horn (Supervisor - Veterinary Science, Research and Support). You will learn what is cancer immunotherapy; what are the potential challenges in the safety assessment of antibodies targeting immune system checkpoints?; Things to consider when designing and running your nonclinical safety programmes for immune checkpoint targets; and more.

See all insights